This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Law, B. K.
Right arrow Articles by Moses, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Law, B. K.
Right arrow Articles by Moses, H. L.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 2002, p. 8184-8198, Vol. 22, No. 23
0270-7306/02/$04.00+0     DOI: 10.1128/MCB.22.23.8184-8198.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Rapamycin Potentiates Transforming Growth Factor ß-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer Cells

Brian K. Law,1* Anna Chytil,1 Nancy Dumont,1 Elizabeth G. Hamilton,1 Mary E. Waltner-Law,2 Mary E. Aakre,1 Cassondra Covington,1 and Harold L. Moses1

Department of Cancer Biology,1 Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee 372322

Received 16 July 2002/ Accepted 5 September 2002

Transforming growth factor ß (TGF-ß) induces cell cycle arrest of most nontransformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth-inhibitory effect of TGF-ß. TGF-ß overexpression inhibits tumorigenesis, and abolition of TGF-ß signaling accelerates tumorigenesis, suggesting that TGF-ß acts as a tumor suppressor in mouse models of cancer. A screen to identify agents that potentiate TGF-ß-induced growth arrest demonstrated that the potential anticancer agent rapamycin cooperated with TGF-ß to induce growth arrest in multiple cell lines. Rapamycin also augmented the ability of TGF-ß to inhibit the proliferation of E2F1-, c-Myc-, and V12H-Ras-transformed cells, even though these cells were insensitive to TGF-ß-mediated growth arrest in the absence of rapamycin. Rapamycin potentiation of TGF-ß-induced growth arrest could not be explained by increases in TGF-ß receptor levels or rapamycin-induced dissociation of FKBP12 from the TGF-ß type I receptor. Significantly, TGF-ß and rapamycin cooperated to induce growth inhibition of human carcinoma cells that are resistant to TGF-ß-induced growth arrest, and arrest correlated with a suppression of Cdk2 kinase activity. Inhibition of Cdk2 activity was associated with increased binding of p21 and p27 to Cdk2 and decreased phosphorylation of Cdk2 on Thr160. Increased p21 and p27 binding to Cdk2 was accompanied by decreased p130, p107, and E2F4 binding to Cdk2. Together, these results indicate that rapamycin and TGF-ß cooperate to inhibit the proliferation of nontransformed cells and cancer cells by acting in concert to inhibit Cdk2 activity.

* Corresponding author. Mailing address: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 612 Preston Research Building, Nashville, TN 37232. Phone: (615) 936-1507. Fax: (615) 936-1790. E-mail: brian.k.law{at}vanderbilt.edu.

Molecular and Cellular Biology, December 2002, p. 8184-8198, Vol. 22, No. 23
0022-538X/02/$04.00+0     DOI: 10.1128/MCB.22.23.8184-8198.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Corsino, P., Horenstein, N., Ostrov, D., Rowe, T., Law, M., Barrett, A., Aslanidi, G., Cress, W. D., Law, B. (2009). A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism. J. Biol. Chem. 284: 29945-29955 [Abstract] [Full Text]  
  • Harradine, K. A., Ridd, K., Saunier, E. F., Clermont, F. F., Perez-Losada, J., Moore, D. H., Epstein, E. H. Jr., Bastian, B. C., Akhurst, R. J. (2009). Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients. Clin. Cancer Res. 15: 5101-5107 [Abstract] [Full Text]  
  • Beeram, M, Tan, Q-T., Tekmal, R., Russell, D, Middleton, A, deGraffenried, L. (2007). Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18: 1323-1328 [Abstract] [Full Text]  
  • Corsino, P., Davis, B., Law, M., Chytil, A., Forrester, E., Norgaard, P., Teoh, N., Law, B. (2007). Tumors Initiated by Constitutive Cdk2 Activation Exhibit Transforming Growth Factor {beta} Resistance and Acquire Paracrine Mitogenic Stimulation during Progression. Cancer Res. 67: 3135-3144 [Abstract] [Full Text]  
  • Law, M., Forrester, E., Chytil, A., Corsino, P., Green, G., Davis, B., Rowe, T., Law, B. (2006). Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes. Cancer Res. 66: 1070-1080 [Abstract] [Full Text]  
  • Kanehira, T., Tani, T., Takagi, T., Nakano, Y., Howard, E. F., Tamura, M. (2005). Angiotensin II Type 2 Receptor Gene Deficiency Attenuates Susceptibility to Tobacco-Specific Nitrosamine-Induced Lung Tumorigenesis: Involvement of Transforming Growth Factor-{beta}-Dependent Cell Growth Attenuation. Cancer Res. 65: 7660-7665 [Abstract] [Full Text]  
  • Biecker, E., De Gottardi, A., Neef, M., Unternahrer, M., Schneider, V., Ledermann, M., Sagesser, H., Shaw, S., Reichen, J. (2005). Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying Mechanisms. J. Pharmacol. Exp. Ther. 313: 952-961 [Abstract] [Full Text]  
  • Rosner, D., McCarthy, N., Bennett, M. (2005). Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res 66: 601-610 [Abstract] [Full Text]  
  • deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., Hidalgo, M. (2004). Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity. Clin. Cancer Res. 10: 8059-8067 [Abstract] [Full Text]  
  • Chytil, A., Waltner-Law, M., West, R., Friedman, D., Aakre, M., Barker, D., Law, B. (2004). Construction of a Cyclin D1-Cdk2 Fusion Protein to Model the Biological Functions of Cyclin D1-Cdk2 Complexes. J. Biol. Chem. 279: 47688-47698 [Abstract] [Full Text]  
  • Song, K., Cornelius, S. C., Reiss, M., Danielpour, D. (2003). Insulin-like Growth Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor-{beta} by Phosphatidylinositol 3-Kinase/Akt-dependent Suppression of the Activation of Smad3 but Not Smad2. J. Biol. Chem. 278: 38342-38351 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»